Key points are not available for this paper at this time.
We propose that a composite score of CD8+ T-cell density in paired biopsies taken before and on-treatment may be a new biomarker to inform on clinical outcomes in early immunotherapy clinical trials.
Dejardin et al. (Thu,) studied this question.